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A B S T R A C T
Background
Despite advances in chemotherapy, prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce
a tumour-antigen-specific anti-tumour immune responses as an alternative treatment for ovarian cancer.
Objectives
To assess feasibility of antigen-specific active immunotherapy for ovarian cancer. Primary outcomes are clinical efficacy and antigen-
specific immunogenicity with carrier-specific immunogenicity and side-effects as secondary outcomes.
Search methods
A systematic search of the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 3, 2009, Cochrane Gynaecological
Cancer Group Specialized Register, MEDLINE and EMBASE databases and clinicaltrials.gov was performed (1966 to July 2009).
Hand searches were conducted of the proceedings of relevant annual meetings (1996 to July 2009).
Selection criteria
Randomised controlled trials (RCTs), as well as non-randomised non-controlled studies that included patients with epithelial ovarian
cancer, irrespective of stage of disease, and treated with antigen-specific active immunotherapy, irrespective of type of vaccine, antigen
used, adjuvant used, route of vaccination, schedule, and reported clinical or immunological outcomes.
Data collection and analysis
Data extraction was performed independently by two review authors. Risk of bias was evaluated with the Delphi-list for RCTs or a
selection of quality domains pivotal to the assessment of non-RCTs and deemed best applicable to the non-randomised non-controlled
studies.
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Main results
Thirty-six studies were included. Response definitions showed substantial variation between trials, which makes comparison of trial
results unreliable. Information on adverse events was frequently limited. Furthermore, reports of both RCTs and non-RCTs frequently
lacked information necessary to assess risk of bias. Serious biases in these trials can thus not be ruled out.
The largest body of evidence is currently available for CA-125 targeted antibody therapy (15 studies: 1505 patients). Non-RCTs of this
CA-125 targeted antibody therapy suggest increased survival in humoral and/or cellular responders. However, three large randomised
placebo-controlled trials did not show any clinical benefit despite induction of immune responses in approximately 60% of patients.
Other small studies targeting many different tumour antigens showed promising immunological results. As these strategies have not
yet been tested in RCTs, no reliable inferences about clinical efficacy can be made. Given the promising immunological results, limited
side effects and toxicity exploration of clinical efficacy in large well-designed RCTs may be worthwhile.
Authors’ conclusions
We conclude that despite promising immunological responses no clinically effective antigen-specific active immunotherapy is yet
available for ovarian cancer. Furthermore, the adoption of guidelines to ensure uniformity in trial conduct, response definitions and
trial reporting is recommended to improve quality and comparability of immunotherapy trials.
P L A I N L A N G U A G E S U M M A R Y
Antigen-specific active immunotherapy for ovarian cancer
Epithelial ovarian cancer is the most frequently diagnosed ovarian malignancy and the leading cause of death from gynaecological
cancers. Standard therapy consists of surgery followed by chemotherapy. Although initial response rates are high, the majority of
patients with advanced disease relapse. No curative treatment is available for recurrent disease. The observation that the presence of
certain immune cells in tumours is associated with improved survival, suggests that stimulation of anti-tumour immune responses,
i.e. immunotherapy, might be a useful approach to improve prognosis of ovarian cancer. In this review, the feasibility of antigen-
specific active immunotherapy is evaluated. Antigen-specific active immunotherapy aims at the induction of tumour-directed immune
responses through the administration of a tumour-antigen, a molecule that is preferentially expressed by tumour cells and can induce
immune responses. As immunotherapy is a novel treatment strategy early phase studies were also included. Information on clinical and
immunological responses, and adverse events was collected.
Thirty-six studies, which included 1780 ovarian cancer patients, were identified between 1966 and 2009. Themost frequently described
strategy (1505 patients in 15 studies) was administration of antibodies targeting CA-125. Most of these primarily evaluated safety and
immunological responses. Five studies described severe flu-like and gastro-intestinal symptoms in 7 to 30% of patients. Antibodies
and immune cells recognising CA-125 were frequently detected, albeit response rates varied between studies. Despite promising
immunological responses, three large studies found equal survival rates for patients treated with placebo or CA-125 directed antibody.
Because there is currently no high quality evidence of clinical benefit, antibody therapy targeting CA-125 should in its current form
not be incorporated in standard treatment.
For strategies not relying on antibody administration, similar conclusions cannot be drawn as these have not yet been tested in large trials
to evaluate clinical efficacy of treatment. These were generally small studies primarily investigating vaccine safety and immunogenicity.
Overall, treatment was well-tolerated, with inflammatory side effects at injection site most frequently reported. Antibodies and immune
cells were induced by most strategies studied, but their clinically efficacy still has to be evaluated in large trials.
Based on a lack of uniformity in included studies, we strongly advocate universal adoption of response definitions, guidelines for adverse
events reporting, and directives for trial conduct and reporting. Furthermore, results from ongoing RCTs should be awaited and furhter
RCTs should be conducted.
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B A C K G R O U N D
Description of the condition
Ovarian cancer is the sixth most common cancer and the seventh
cause of death from cancer in women worldwide (Parkin 2006). It
is the second most common gynaecological cancer and the leading
cause of death from gynaecological cancers in the Western world.
As themajority of ovarian malignancies (80 to 90%) arise from the
epithelium, all statements in the remainder of this review about
ovarian cancer apply to epithelial ovarian cancer only.World-wide
age standardized incidence rates range from 2.6 per 100,000 in
Northern Africa to 13.3 per 100,000 in Northern Europe (Parkin
2006).
Stage of disease at presentation is the most important prognostic
factor. Due to the asymptomatic course of disease, the majority of
patients have extensive disease at presentation (stage III to IV ac-
cording to FIGO classification (Benedet 2000)). Despite standard
treatment, which consists of cytoreductive surgery and platinum-
based chemotherapy, almost all patients with advanced stage dis-
ease at presentation will relapse, with a median progression free
survival (PFS) of only 18 months. When residual or recurrent dis-
ease manifests itself, resistance to chemotherapy often prohibits
further curative therapy, resulting in a disease specific five-year
survival for patients with advanced stage ovarian disease of only
10 to 20% (Agarwal 2006; Thigpen 2000).
Description of the intervention
The immune system seems to play a role in ovarian cancer. This is
reflected in the observation that in more than half of ovarian can-
cer patients, T- cells are present within tumour-islets (Raspollini
2005; Zhang 2003). Patients with advanced ovarian cancer, whose
tumour is infiltrated by theseT-cells, have a better clinical outcome
compared to patients without these tumour-infiltrating T-cells
(Dong 2006; Raspollini 2005; Zhang 2003). More specifically,
higher numbers of cytotoxic T-cells, which can directly recognise
and kill tumour cells, and increased ratios between cytotoxic T-
cells (CD8+) and helper T-cells (CD4+) within the tumour ep-
ithelium are associated with improved survival (Sato 2005).
Immunotherapy is one of the novel therapeutic strategies under
investigation for ovarian cancer. It aims to induce or enhance active
immune responses directed towards the tumour and to consolidate
anti-tumour effects of standard therapy, delay and possibly prevent
progression of disease. More specifically, antigen-specific active
immunotherapy aims at activation of the adaptive immune system
directed towards a specific target antigen through administration
of a molecular defined antigen-specific vaccine to the patient.
How the intervention might work
An antigen is a molecule, usually a protein or polysaccharide,
which can stimulate an immune response. Tumour antigens can
be subdivided into different categories such as mutated self pro-
teins, products of oncogenes (e.g. Her-2/Neu), mutated tumour
suppressor genes (e.g. p53), and aberrantly expressed self proteins
(e.g. sperm protein 17, MAGE-1). Numerous tumour-associated
antigens are known in ovarian cancer. To obtain a tumour-spe-
cific immune response, immunotherapy exploits the differential
expression of antigens between normal and tumour cells. A ma-
jor challenge concerning the safety of immunotherapy lies in the
prevention of auto-immunity i.e. induction of immune cells that
preferentially recognise and kill tumour cells, but avoid destruc-
tion of normal body cells. From a theoretical point of view, other
possible side effects include allergic reactions to components of
the vaccine and inflammatory reactions at the site of injection.
Why it is important to do this review
Several immunotherapeutic strategies are now being employed us-
ing different tumour antigens. These studies have, however, gen-
erally not yet evolved past phase I/II studies. To our knowledge,
no systematic review of antigen-specific active immunotherapy in
ovarian cancer has been carried out so far.
The immunogenicity and clinical efficacy of antigen-specific ac-
tive immunotherapy in ovarian cancer is evaluated in this review. A
systematic review about this topic is useful to ascertain the achiev-
ability of this treatment modality for ovarian cancer.
O B J E C T I V E S
The primary objective of this review was to assess the efficacy
(i.e. clinical and/or immunological responses) of antigen-specific
active immunotherapy for the treatment of ovarian cancer. The
secondary objective was to establish which immunotherapeutic
strategies combined with which tumour antigens provide the best
immunological and clinical results.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We anticipated that there would be no RCTs on this subject.
Therefore we also included phase I, phase II non-randomised and
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non-controlled and if available phase III studies. We realised that
results from non-randomised non-controlled studies cannot read-
ily be extrapolated to the general population. Nevertheless, we felt
that given the anticipated lack of RCTs, inclusion of these studies
into this review was justifiable.
Types of participants
Women diagnosed with epithelial ovarian cancer, irrespective of
stage of disease. However, as patient populations may differ sub-
stantially between different types of studies to be included in this
review, for each study we documented what type of patient was
included into the study (e.g. patients with end-stage disease or
patients with residual disease).
Becausewe anticipated that therewouldnot bemany studieswhich
included patients with ovarian cancer only, we also included im-
munotherapeutic studies in cancer patients that included at least
two patients with ovarian cancer; with the additional requirement
that the results for these individual patients were separately iden-
tifiable from the study publication or communication with the
author and only data on these patients were extracted for the re-
view. We were fully aware of the vigilance necessary when drawing
conclusions based on studies with such small numbers, but felt
that given the anticipated lack of large RCTs, inclusion of these
studies into this review was justifiable.
Types of interventions
Antigen-specific active immunotherapy is defined as therapy
which aims at inducing an adaptive immune response directed
towards the tumour by means of administration of a specific well-
defined tumour antigen. We compared interventions with each
other based on the above-mentioned characteristics.
We included all interventions that aimed at antigen-specific active
immunotherapy irrespective of type of vaccine, antigen used, ad-
juvant used, route of vaccination, vaccination schedule.
Types of outcome measures
Primary outcomes
Clinical efficacy
To assess clinical efficacy we evaluated:
1. Tumour responses to immunotherapy (complete/partial re-
sponse, stable/progressive disease), as measured by:
• CA-125 levels according to or transposable to Gynecologic
Cancer Intergroup (GCIG) criteria (Rustin 2004)
• Tumour response according to WHO criteria (WHO
1979) or Response Evaluation Criteria in Solid Tumors Group
(RECIST) criteria (Therasse 2000)
2. If available we evaluated responses to post-immunotherapy
treatment, as there are indications in small cell lung cancer that
patients treated with chemotherapy after immunotherapy have in-
creased survival as opposed to patients who did not receive im-
munotherapy (Antonia 2006).
3. If available, survival differences based on treatment with im-
munotherapy.
Antigen-specific immunogenicity
We recorded the number of observed antigen-specific humoral and
cellular responses.Whenpossible, we separately reported responses




As certain immunotherapeutic strategies rely on the use of carriers
that may be the subject of an immune response besides the in-
tended antigen-specific immune response, we recorded informa-
tion on the induction of carrier-specific immune responses when
appropriate.
Adverse events
To obtain imformatiojn on the toxicity of antigen-specific im-
munotherapy, we extracted data on adverse events observed and
reported in the different studies. Adverse events were categorised
as local adverse events at the site of immunisation or systemic ad-
verse events (all other reported adverse events). Systemic adverse
events were subdivided into autoimmunity, allergic reactions and
other adverse events occurring after immunisation.
Search methods for identification of studies
CochraneCentral Register of ControlledTrials (CENTRAL) Issue
3, 2009,CochraneGynaecological CancerGroupSpecializedReg-
ister as well as the prospective trial register www.clinicaltrials.gov
were searched. Furthermore, we searched MEDLINE (1966 to
July 2009) and EMBASE (1974 to July 2009) according to the
search strategies listed in Appendix 1 and Appendix 2.
Hand searching was undertaken of abstracts in the proceedings
of annual meetings of Society of Gynecologic Oncologists, the
American Association for Cancer Research and the International
Society for Biological Therapy of Cancer (1996 to July 2009).
The bibliography of each primary reference and of recent reviews
of immunotherapy for ovarian cancer was checked for additional
study publications. In addition we wrote to specialists involved
in research regarding immunotherapy for ovarian cancer for in-
formation about the results of unpublished or ongoing studies.
Relevant data were included in this review.
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There were no language restrictions other than those inherent to
the databases surveyed.
The search strategies used have been developed and executed by
the author team.
Data collection and analysis
Selection of studies
All titles and abstracts retrieved by electronic searchingwere down-
loaded to ReferenceManager, duplicates were removed and the re-
maining references were examined by two review authors (HWN
and NL) independently. Those studies which clearly did not meet
the inclusion criteria were excluded and copies of the full text of
potentially relevant references were obtained. The eligibility of re-
trieved papers was assessed independently by two review authors
(HWN and NL). Differences between review authors were re-
solved by discussion or by appeal to a third review author if nec-
essary (TD). Reasons for exclusion were documented.
Data extraction and management
For included studies, data on characteristics of patients and in-
terventions, study quality and endpoints were extracted indepen-
dently by two review authors (HWN and NL) onto a data extrac-
tion form specially developed for the review (Appendix 4).
Where data on clinical efficacy and antigen-specific immunogenic-
ity were missing from reports, we attempted to contact the au-
thors to obtain the missing information. Results were checked for
accuracy by a third review author (WH or TD).
Assessment of risk of bias in included studies
Risk of bias in RCTs complying with our selection criteria were as-
sessed according to the Delphi-list (Verhagen 1998). Studies were
evaluated based on randomisation, concealment of treatment allo-
cation, blinding of patient, caregiver and outcome assessor, base-
line similarity of groups, intention-to-treat (ITT) analysis, speci-
fication of eligibility criteria, and presentation of point estimates
and measures of variability for the primary outcome measures.
No standard tools to evaluate validity are available for non-RCTs.
Instead, for these studies we evaluated the risk of bias using the
following four domains (Table 1):
• sample definition and selection
◦ clear definition of inclusion / exclusion criteria
◦ representative selection
◦ adequate description of baseline characteristics
• interventions:
◦ clear specification
◦ concurrent / concomitant treatment
• outcomes:
◦ specifications of outcome measures
◦ relevance of outcome measures
◦ reporting of outcome measures
• statistical analysis:
◦ adequate rationale for number of patients included
◦ adequate description withdrawal / exclusion during
the study
◦ adequate presentation of results.
These domains were selected as representative for and applicable
to non-randomised non-controlled studies from a list of 12 quality
domains and items deemed to be pivotal to the assessment of non-
RCTs (Deeks 2003).
Risk of bias assessment was carried out by two review authors
(HWN and NL). Discrepancies between review authors were be
solved by discussion; if necessary a third author (WH or TD) was
consulted.
Data synthesis
This review provides a narrative analysis, because the included
studies are highly heterogenous regarding intervention and out-
come measures. Furthermore data in publications were often pre-
sented with insufficient details (lack of standard deviations (SDs)
or only some of the multiple outcomes presented), and additional
information from report authors was difficult to obtain. Therefore
we felt that quantitative meta-analysis and calculation of effect size
estimates would neither be meaningful nor appropriate in this re-
view. We limited analysis to a structured summary and discussion
of available studies and findings.
R E S U L T S
Description of studies
Results of the search
From the electronic searches of MEDLINE and EMBASE, 56
out of 311 abstracts were selected as potentially compliant with
the selection criteria and full texts were retrieved. Evaluation of
the retrieved full texts resulted in the exclusion of 26 papers (see
Excluded studies). In addition to the 30 selected full texts, another
14 abstracts were identified by hand searching the proceedings of
the periodic meetings specified in the methods section. Authors
were contacted for manuscripts, but no full texts were obtained
for these abstracts. Together the 44 selected full texts and meeting
abstracts described a total of 35 studies. Search of the prospective
trial register www.clinicaltrials.gov resulted in identification of an
additional 26 studies. For only four of these a full text or meeting
abstract could be retrieved and only one study complied with our
inclusion criteria (Sabbatini 2007). The remaining studies were
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either ongoing (n = 15) or completed but not yet published (n
= 6). Search of CENTRAL (Issue 3, 2009) did not identify any
additional studies. Thus a total of 36 studies were included in this
review. Generally, the most recent peer-reviewed publication was
selected as the primary reference.
Included studies
The 36 studies included in this reviewwere all published in English
(Characteristics of included studies, Table 2).
Design
As expected themajority of studies were uncontrolled phase I or II
studies (27 out of 36).Only three studies were randomised placebo
controlled studies (Berek 2001; Berek 2004; Berek 2009). Ran-
domised allocation of patients to different regimens was used in
six studies (Braly 2009; Chu 2008; Freedman 1998; Herrin 2007;
Method 2002; Sabbatini 2006). In four studies the immunogenic-
ity of a previously applied immuno scintigraphic agent was retro-
spectively studied (Möbus 2003; Noujaim 2001; Schultes 1998;
Wagner 1993).
Sample sizes
The median number of patients treated per study was 20 (range 2
to 371). Nine studies included less than ten patients. Six studies
also included patients with other types of cancer (Brossart 2000;
Gulley 2008; Mohebtash 2009; Sandmaier 1999; Ströhlein 2009;
Tsuda 2004). A sample size calculation or rationale was provided
for six studies only (Berek 2004; Berek 2009; Braly 2009; Leffers
2009a; Sabbatini 2006; Sabbatini 2007).
Participants
As was expected, the disease status at study entry varied largely be-
tween studies. Patients with evidence of residual or recurrent dis-
ease after treatment were most frequently included (13 out of 36)
(Freedman 1998; Gulley 2008; Leffers 2009a; Ma 2002; Method
2002;Mohebtash 2009; Nishikawa 2006; Pfisterer 2006; Reinartz
2004; Sandmaier 1999; Schultes 1998; Ströhlein 2009; Wagner
1993). Four studies included patients with and without evidence
of disease after prior therapy (Braly 2009; Chianese-Bullock 2008;
Odunsi 2007; Tsuda 2004). Eight studies included patients with
complete response to therapy for primary or recurrent disease
(Berek 2001; Berek 2004; Berek 2009; Chu 2008; Diefenbach
2008; Odunsi 2007a; Sabbatini 2000; Sabbatini 2007). In addi-
tion, one study also included patients with minimal residual dis-
ease after primary therapy (Sabbatini 2006). In one study treat-
ment was administered together with adjuvant chemotherapy af-
ter primary cytoreductive surgery (Braly 2009). For the remaining
nine studies disease status at entry was not reported.
Interventions
Themajority of studies described antibody therapy (18 out of 36),
usually targeting CA-125 (15 out of 18). Most studies included
only one target antigen in the vaccine, but in six studies multiple
antigens were simultaneously targeted (Chianese-Bullock 2008;
Chu 2008; Gulley 2008;Mohebtash 2009; Sabbatini 2007; Tsuda
2004). Antibodies were usually administered intravenously (11
out of 18). For other vaccine types, subcutaneous injections were
most common (13 out of 18).
Concurrent treatment with immunomodulatory drugs was not al-
lowed in 8 out of 36 studies. In an additional 11 studies, con-
comitant immunomodulatory agents were not part of the studied
intervention, but no explicit statements were made about prohi-
bition of such drugs in the protocol. In ten studies immunomod-
ulatory drugs were part of the protocol (i.e. carboplatin-paclitaxel,
cyclophosphamide, IL-2 +/- GM-CSF, or diphenhydramine) and
one study allowed interruption of immunotherapy by chemother-
apy for progressive disease (Reinartz 2004). Furthermore, two ret-
rospective studies explicitly mentioned concurrent chemotherapy
(Möbus 2003; Wagner 1993).
Outcomes
Information on immunological responses, clinical responses, sur-
vival and adverse events was available for 34, 21, 25 and 28 studies
respectively.
Excluded studies
A summary of the excluded studies is given in the table of
Characteristics of excluded studies. Frequent reasons for exclusion
were inclusion of too few ovarian cancer patients and the impos-
sibility to distinguish results of ovarian cancer patients from other
patients.
Risk of bias in included studies
The assessment of risk of bias by means of the Delphi list was
hindered by the fact that for five of the nine RCTs only meeting
abstracts were available (Table 3). The four trials for which full
texts were retrieved also did not report on some items of theDelphi
list. Overall this resulted a median of four unreported items (one
to five) per study. With this substantial lack of information, it is
difficult to make any statement about biases in and validity of the
randomised trials.
An overview of the assessment of study report quality and risk of
biases of the non-randomised studies is provided in Table 4. Im-
portant observations from this table are the lack of clearly defined
in-/exclusion criteria in 8 out of 27 studies combined with the seri-
ous under-reporting of baseline characteristics (16 out of 27 stud-
ies) which makes it impossible to evaluate whether the study pop-
ulations were representative of the true population. Although the
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investigational interventions were well described in themajority of
studies (24 out of 27), information on the allowance or application
of concomitant immunomodulatory treatment was frequently ab-
sent (18 out of 27). Albeit a clear description of outcome measures
was available for 17 studies, an adequate calculation of sample size
based on a clearly defined primary outcome measure was available
for only two studies. Furthermore, the applied checklist shows that
the justification of withdrawals and exclusions during the study
as well as the presentation of study results are items that require
serious attention in the reports of these non-randomised studies.
Based on the above, the risk of bias in the studies included in this
systematic review cannot be neglected. Especially selection bias
(selection of a treatment population not comparable to control
group or true population), attrition bias (inadequate reporting of
withdrawal and exclusions during the study resulting in possible
over- or underestimation of effect) and selective reporting bias are
likely to affect the studies included in this review. The effects of






Clinical responses to therapy were evaluated in 21 studies (Table
5). In the reports on these studies, criteria for evaluation and/
or explicit description of tumour responses per patient as well
as the time point at which the evaluation took place were fre-
quently not available. For studies that did mention evaluation
of tumour responses, response outcomes were based on either
CA-125 levels combined with tumour imaging (Chianese-Bullock
2008; Diefenbach 2008; Ehlen 2005; Gordon 2004; Gulley 2008;
Leffers 2009a; Sabbatini 2006; Ströhlein 2009; Tsuda 2004; van
Zanten-Przybysz 2002), CA-125 alone (Nicholson 2004; Wagner
1993) or imaging alone (Odunsi 2007; Reinartz 2004). Only two
studies explicitly mentioned evaluation of imaging according to
the internationally accepted WHO or RECIST criteria (Leffers
2009a; Reinartz 2004; Tsuda 2004) and only two studies evalu-
ated CA-125 levels according to GCIG criteria or described CA-
125 levels in such a way that evaluation according to these cri-
teria was possible for at least some patients (Leffers 2009a; van
Zanten-Przybysz 2002). Strikingly, five studies stated that evalu-
ation of tumour responses was performed, but results could not
be found in the publications (Diefenbach 2008; Gulley 2008;
Method 2002; Reinartz 2004; Wagner 1993). Complete or par-
tial tumour responses in patients with evidence of disease at study
entry were reported by only two studies (Gordon 2004; Odunsi
2007) in a small fraction of patients (3 out of 15 and 1 out of 18
respectively). These results need to be interpreted with caution as
criteria for response evaluation were not defined.
Responses to ’secondary’ treatment after immunotherapy
Although studies generally have a period of follow-up to obtain
information on survival, in the majority of studies no report is
given of subsequent treatmentwith and response to secondary che-
motherapy. Seven studies mention that patients were treated with
chemotherapy after immunotherapy (Berek 2004; Gordon 2004;
Möbus 2003; Odunsi 2007; Reinartz 2004; Ströhlein 2009; van
Zanten-Przybysz 2002), but only two studies, both investigating
a monoclonal antibody targeting CA-125, report response to sec-
ondary chemotherapy in relation to immunological responses to
immunotherapy (Gordon 2004; Reinartz 2004). In a preliminary
report clinical responses of 28 out of 42 patients treated with che-
motherapy for clinically relevant progression during or after anti-
body therapy were reported in conjunction with the induction of
human-anti-mouse and anti-anti-idiotype antibodies. Although
both patients with a complete response had strong humoral re-
sponses, similar or stronger antibody responses were also observed
for patients with stable or progressive disease (Reinartz 2004). In
the other study, shortly after monotherapy with a monoclonal an-
tibody, 13 out of 20 patients received chemotherapy combined
with the monoclonal antibody. In this study, clinical responses
to chemo-immunotherapy, were only observed in patients with
cellular responses to CA-125 and/or autologous tumour (Gordon
2004).
Survival
Definitions of survival used in the different studies varied greatly
(Table 6 and Table 7). Furthermore, reliable statements about sur-
vival (dis)advantages can only be made based on RCTs. Only three
studies were designed to primarily evaluate survival, however, no
statistically significant differences in time to relapse and/or overall
survival (OS) were found between patients treated with a mono-
clonal antibody or placebo (Berek 2001; Berek 2004; Berek 2009).
Many non-RCTs have also evaluated survival, frequently by com-
paring survival of patients with robust immunological responses
to patients with no or weak immunological responses to treatment
(Table 6 and Table 7). These results should be interpreted with
great caution as shorter survival in non-responders could merely
be a reflection of the general condition of these patients and well-
known clinical and pathological prognostic parameters.
Antigen-specific immunogenicity
Humoral responses
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Monoclonal antibodies may induce anti-idiotype antibodies
(Ab2), directed primarily against the administered monoclonal
antibody, as well as anti-anti-idiotype antibodies (Ab3) directed
towards the target antigen. Anti-idiotype and anti-anti-idiotype
antibodies were evaluated in 10 and 9 out of 18 studies respec-
tively (Table 8 and Table 9). Response percentages greatly varied
(Ab2: 3 to 100%, Ab3: 0 to100%).
Eight studies (10 out of 18) of other vaccine types evaluated the
induction of antigen-specific antibodies by ELISA, however only
two studies clearly definedwhen an antibody titre or concentration
was considered positive (Table 10) (Diefenbach 2008; Sandmaier
1999). Large differences in percentages of patients with measur-
able antigen-specific antibodies (IgG: 0 to 96%) existed. Possible
explanations for these broad ranges are differences in 1) response
definition, 2) number of treatment cycles after which humoral re-
sponses were measured and 3) targeted antigen.
Cellular responses
The induction of T-cells against the target antigen was investi-
gated in 11 out of 18 monoclonal antibody studies (Table 11).
The presence of antigen-specific T-cells was evaluated by com-
monly used tests, such as IFN-γ ELISPOT (Ehlen 2005; Gordon
2004; Method 2002; Sabbatini 2006), proliferation assay (Ma
2002; Noujaim 2001; van Zanten-Przybysz 2002), cytokine pro-
filing (Noujaim 2001; Pfisterer 2006) and IFN-γ secretion assay
(Ströhlein 2009). One study used the leukocyte migration inhi-
bition assay (Wagner 1993), which nowadays is rarely used. As
described above for humoral responses, response definitions were
frequently lacking or inadequate. Nevertheless, cellular immunity
against CA-125 was reported for 21 to 80% of patients. Antibody
treatment targeting themembrane folate receptor however did not
induce cellular responses (van Zanten-Przybysz 2002). Recogni-
tion of autologous tumour cells by inducedT-cells was determined
in two studies only, with positive responses in 5 out of 8 and 1 out
of 2 patients respectively (Gordon 2004; Ströhlein 2009).
Antigen-specific cellular immune responses were evaluated for 12
out of 18 studies using other vaccine types (Table 12). The most
frequently used assay was the IFN-γ ELISPOT assay, which was
sometimes used to separately analyse CD4+ and/or CD8+ cells.
Again response definitions for positive and/or vaccine-induced
responses were frequently absent or unclear (8 out of 18). In
four studies NY-ESO-1 specific T-cells were induced, with per-
centages of patients with NY-ESO-1-specific CD8+ ranging from
33 to 67% (Diefenbach 2008; Odunsi 2007; Odunsi 2007a).
After treatment with a vaccine targeting p53, p53-specific T-
cells were observed in approximately 70% of patients, irrespec-
tive of whether short peptides or peptide-pulsed dendritic cells
were used (Herrin 2007). Lastly, studies targeting multiple anti-
gens demonstrated antigen-specific cellular immunity with vary-
ing immunogenicity of the different antigens targeted (Brossart
2000; Chianese-Bullock 2008; Chu 2008; Tsuda 2004).
Secondary outcomes
Carrier-specific immunogenicity
The majority of studies using a monoclonal antibody (17 out of
18) used a murine antibody and one study used a chimeric an-
tibody construct (van Zanten-Przybysz 2002). Next to antigen-
specific immunity, the induction of human-anti-mouse antibod-
ies (HAMA) using HAMA-specific ELISA assays was assessed in
13 studies (Table 13). HAMA were present in 4 to 97% of pa-
tients immunized (Berek 2004; Braly 2009; Ehlen 2005; Gordon
2004;Method 2002;Möbus 2003; Pfisterer 2006; Reinartz 2004;
Sabbatini 2006; Schultes 1998). It seems that the large variation
between studies cannot be attributed to differences in dosage, but
is best ascribed to different definitions of a HAMA response i.e.
some studies only report robust responses, whereas others report
all responses above a certain threshold. Furthermore, the point in
time at which HAMA titers were measured is of importance as
responses increase in frequency and strength with repeated admin-
istrations of the antibody (Gordon 2004; Method 2002; Möbus
2003).
Although six studies investigated synthetic carbohydrate antigens
conjugated to the keyhole limpet haemocyanin (KLH) carrier pro-
tein (MacLean 1992; MacLean 1996; Sabbatini 2000; Sandmaier
1999; Sabbatini 2007), only one study reported on KLH-specific
immunity (Sandmaier 1999). In this study, proliferative responses
to stimulationwithKLHand theKLH-antigen complexwere sub-
stantially stronger than responses to the synthetic carbohydrate
itself in all ovarian cancer patients tested, similar to what has pre-
viously been reported for viral vectors.
The use of vaccinia and fowlpox viruses as viral vectors was re-
ported by three studies (Gulley 2008; Mohebtash 2009; Odunsi
2007a). Anti-vector immune responses were reported to be inves-
tigated by only one of these and occurred in all ovarian cancer
patients treated (Gulley 2008).
Adverse events
For this review, adverse events were defined as any adverse change
in health or side-effect that occurred in a person who participated
in the clinical study while the patient was receiving the treatment,
irrespective of whether the event could be attributed to the treat-
ment received.
Although 28 studies mentioned adverse events, sufficiently de-
tailed information on adverse events occurring during the study
was available for only 21 out of 36 studies. Local adverse events
were explicitly mentioned for 16 studies all of which used local ad-
ministration of the vaccine (i.e. intradermal, intramuscular or sub-
cutaneous injection). Although these studies report the presence
of injection site reactions, 50% did not further specify the type of
local adverse events witnessed.When local adverse events were fur-
ther specified, these were best summarized as pain at the injection
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site and local inflammatory responses (erythema, induration, pru-
ritis). In one study 3 out of 30 patients developed a small abscesses
and ulceration upon intradermal injection, after which the adju-
vant was omitted from the vaccine for these patients (Freedman
1998).
Systemic adverse events occurred in 23 studies and were not ob-
served in 2 studies. For the remaining 11 studies no information
on systemic adverse events could be deduced from themanuscript.
Autoimmunity was reported by two studies. In one study a patient
with strong immunological responses to the vaccine developed a
symptomatic hypothyroidism necessitating replacement therapy
(Diefenbach 2008). A minor induction of anti-nuclear antibodies
(grade I according to Common Terminology Criteria for Adverse
Events (CTCAE) v3.0 (Trotti 2003)) was described for two pa-
tients receiving a multi-peptide vaccine (Chianese-Bullock 2008).
Allergic reactions were described for a total of 14 patients (Berek
2009; Braly 2009; Ehlen 2005; MacLean 1992; Möbus 2003;
Pfisterer 2006; Ströhlein 2009). Allergic reactions were mild and
easily managed, e.g. hypersensitivity, allergic exanthema, and ur-
ticaria. When study treatment was continued, this did not result in
renewed allergic reactions (Braly 2009; Ehlen 2005;Möbus 2003;
Pfisterer 2006).
Other systemic adverse events reported, irrespective of whether at-
tributable to the investigated drug, included hematologic changes
(e.g. anaemia, leucopenia), flu-like symptoms (including fatigue,
myalgia, arthralgia, headache, fever and chills) and gastrointesti-
nal events (e.g. nausea, vomiting, diarrhoea, and abdominal pain),
most of which were classified as grade I or II events. Grade III or
IV adverse events were reported by eleven studies. For two studies
it was however unclear whether the participating ovarian cancer
patients experienced these events (Gulley 2008; Tsuda 2004) and
in one study serious adverse events undoubtedly reflected progres-
sive disease (Leffers 2009a). In the one study, which investigated
p53-based immunization strategies combinedwith IL-2, grade III/
IV adverse events were observed in 42% of patients in each arm
of the study and ascribed to the IL-2 adjuvant, which was there-
after omitted from the regimen for these patients (Herrin 2007).
Severe or life-threatening flu-like symptoms and gastro-intestinal
events were observed in 7 to 30% of patients in 7 studies inves-
tigating monoclonal antibodies targeting CA-125 (Berek 2004;
Berek 2009; Braly 2009; Ehlen 2005; Gordon 2004; Pfisterer
2006; Sabbatini 2006). However as no differences in serious ad-
verse events were observed between patients treated with themon-
oclonal antibody and placebo controls, it is unlikely that these can
be attributed to the monoclonal antibody treatment.
D I S C U S S I O N
The aim of this review was to evaluate clinical and immunolog-
ical efficacy of antigen-specific active immunotherapy in ovarian
cancer, whilst also obtaining an impression of safety and tolera-
bility of this treatment modality. The antigen-specific active im-
munotherapy described in this review can largely be divided into
two strategies (1) the administration of antibodies targeting a spe-
cific tumour antigen and (2) the administration of or parts of a
specific tumour antigen itself. As expected, most studies were non-
RCTs.
Antigen-specific humoral and/or cellular immunogenicity of the
different interventions showed great variation for both mono-
clonal antibody studies and studies using other strategies. This
variation may at least be partially attributed to the variation in im-
munological response definitions used by the different studies. It is
therefore not possible to reliably compare studies and infer which
intervention and/or immunization strategy is most promising for
the induction of strong anti-tumour immunity. Furthermore, only
two studies evaluated recognition of autologous tumour cells in
vitro and none evaluated immune responses at the tumour site.
Although obtaining autologous tumour material may be burden-
some, such assays would be extremely valuable as they comprise
true interactions between induced immunity and tumour cells and
could as such provide important information on how to continue
improvement of immunotherapeutic strategies to reach clinical ef-
fectiveness.
Clinical responses to immunotherapy (i.e. tumour responses, re-
sponses to secondary treatment and survival benefits) were ob-
served only incidentally and when described reliability of results
was questionable due to the absence of clear response definitions.
Furthermore, for studies in which a monoclonal antibody target-
ing CA-125 was used, the use of CA-125 as a marker for clinical
response is questionable. An additional important comment re-
garding the likelihood of clinical responses to immunotherapy es-
pecially in uncontrolled studies which frequently include patients
with recurrent disease, is the fact that this likelihood may be af-
fected by the disease status at start of treatment (Leffers 2009).
The indication for immunotherapeutic treatment in the adjuvant
setting is supported by the observation of enhanced antigen-spe-
cific responses to immunotherapy when combined with chemo-
therapeutic agents currently or previously used in the primary
treatment of ovarian cancer i.e. docetaxel or cyclophosphamide
(Garnett 2008; Laheru 2008). Three large RCTs using a mono-
clonal CA-125 antibody in the adjuvant setting after successful
primary therapy however did not demonstrate any differences in
time to relapse and/or OS between the treatment and placebo
arm (Berek 2001; Berek 2004;Berek 2009), which indicates that
despite immunogenicity, CA-125 targeted monoclonal antibody
therapy is clinically ineffective. For the studies of other vaccine
types, no such conclusions can be made at this time as large RCTs
and more studies in the adjuvant, rather than recurrent setting
have yet to be performed for the different strategies.
Adverse events, reported in sufficient detail for interpretation, were
reported in 60% of studies. A distinction was made between lo-
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cal and systemic events. The latter were further subdivided in au-
toimmunity, allergy and other adverse events. We did not evaluate
whether adverse events could be or were considered attributable
to the treatment studied, although for local adverse events this
is indisputably the case. Inflammatory reactions and pain at the
injection site were frequently reported for studies using intrader-
mal, subcutaneous or intramuscular application. Severe or life-
threatening systemic adverse events were reported by 11 studies,
7 of which investigated monoclonal antibodies targeting CA-125.
For these monoclonal antibody studies, no pattern suggestive of
a underlying treatment-associated process could be identified and
events were often considered to be associated with ovarian cancer
progression. Serious adverse events in another study were consid-
ered to be related to IL-2 given as an adjuvant to the antigen-
specific active immunization.
A disturbing observation regarding adverse events is the lack of
uniformity in adverse event reporting. Reporting of safety and
tolerability of new treatment strategies should have high priority
in all studies of investigational drugs, especially in uncontrolled
phase I and II studies. To promote uniformity in adverse event
evaluation and reporting as well as the comparability of adverse
events between studies, in addition to the NCI CTCAE (Trotti
2003), theBrightonCollaboration (Brighton Collaboration 2009)
has committed itself to develop standardized, widely disseminated
and globally accepted case definitions for an exhaustive number
of adverse events following immunisation as well as guidelines for
data collection, analysis, and presentation. These case-definitions
and guidelines are freely available and we strongly recommend
that, where applicable, these are used for all immunotherapeutic
studies.
Interestingly, for six studies described in this review, information
from the study was collected from a meeting abstract only and
often this meeting abstract was several years old. The lack of full
text manuscripts, even after contacting abstract authors, strongly
suggests the existence of a publication bias. To avoid the disap-
pearance of negative studies, registration of trials in a prospective
trial register is widely recommended and supported by the Inter-
national Committee of Medical Journal Editors (ICMJE). How-
ever, initially in 2005 registration was only requested for RCTs.
Since July 1, 2008 all trials prospectively assigning human partic-
ipants to one or more health-related interventions to evaluate the
effects on health outcomes are required to register in a clinical trial
register approved by theWHO. From the ongoing studies section
it is however apparent that despite registration in a prospective
trial register, studies may suffer from publication bias as several
relatively small studies started more than five years ago have not
yet been published to date or closed according to the trial register.
In addition to registration in trial registers, the uniform require-
ments for manuscripts submitted to biomedical journals drafted
by the ICMJE encourage uniformity in reporting of clinical trials
by stating ethical principles in conduct and reporting of research
as well as proving recommendations relating to specific elements
of editing and writing. As is obvious from this review, the scientific
community might benefit substantially if also early phase uncon-
trolled clinically trials would strive for uniformity in trial conduct
and reporting.
This review also emphasizes another aspect of immunotherapeutic
studies that warrants serious attention in the immunotherapeutic
scientific community i.e. the lack of consensus on 1) what assays to
use to establish immunogenicity of an intervention (Britten 2008),
2) what cut-offs to use to define true immunological responses
and 3) response definitions for clinical efficacy. Given these large
inconsistencies it is evident that the elucidation of what type of
immunological response is necessary for and/or a surrogate marker
of clinical activity of an immunotherapeutic intervention is bur-
densome.
In summary, this review describes 36 immunotherapy studies in
ovarian cancer patients. The most striking observations of this
review unfortunately do not concern the aim of the review, but
address the lack of uniformity in conduct and reporting of early
phase immunotherapy studies. When temporarily discarding this
methodological heterogeneity, it seems that although all strategies
described are capable of inducing immunological responses, be it
humoral or cellular, clinically effectiveness has thus far not been
convincingly demonstrated. The largest body of evidence is avail-
able for CA-125 directed antibody therapy, which has been stud-
ied in 1505 patients participating in 15 studies. As complete or
partial clinical responses were reported in only one study and three
large RCTs did not demonstrate any clinical benefit of antibody
treatment, we feel that it is unlikely that clinical effectiveness of
CA-125 directed antibody therapy for ovarian cancer will ever be
obtained. However, in view of the immunological responses to and
the usually mild side-effects, we feel that further investigation of
other antigen-specific active immunotherapy strategies in ovarian
cancer is worthwhile.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At this point in time, there is no evidence of effective immunother-
apy for ovarian cancer. Although promising immunological re-
sponses have been observed for most strategies evaluated, these do
not coincide with clinical benefits for ovarian cancer patients. Fur-
thermore, there are currently no immunological surrogate mark-
ers that correlate with clinical outcomes. Until evidence of true
clinical effectiveness is available, immunotherapy should therefore
not be offered as an alternative to standard therapy for primary or
recurrent ovarian cancer.
Implications for research
Our primary recommendation relates to the necessity of unifor-
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mity in trial conduct and reporting. Not until universally accepted
immunological and clinical response definitions and guidelines for
adverse events reporting are adopted in immunotherapeutic stud-
ies, will it be possible to make any inferences about the achievabil-
ity of immunotherapy as a treatment for ovarian cancer. Further-
more, expanding evaluation of immunogenicity to include recog-
nition of autologous tumour is advisable. Given the usually mild
side-effects and the immunological responses witnessed in most
studies, we feel that further investigation of antigen-specific active
immunotherapy other than CA-125 targeted antibody therapy in
ovarian cancer in RCTs is worthwhile.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Berek 2001
Methods Randomized placebo controlled trial
Participants 252 stage III/IV ovarian cancer patients after successful primary surgery and chemotherapy
Interventions Intravenous monoclonal antibody (oregovomab - CA125) versus Intra. placebo
Outcomes Survival (time to relapse)
Immune responses: humoral (Ab2, HAMA)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk methodof randomisationnot described, only abstract avail-
able




Low risk double blind study
Berek 2004
Methods Randomized placebo controlled phase II Trial
Participants 145 stage III/IV ovarian cancer patients with complete clinical response to primary therapy
Interventions Intravenous monoclonal antibody (oregovomab) versus Intra. placebo
Outcomes Survival (time to relapse / overall survival)




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk method of randomisation not described
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Berek 2004 (Continued)
Allocation concealment? Unclear risk not described
Blinding?
All outcomes
Unclear risk not described
Berek 2009
Methods Randomized placebo controlled phase III trial
Participants 371 stage III/IV ovarian cancer patients with complete clinical response to primary therapy
Interventions Intravenous monoclonal antibody (oregovomab) versus Intra. placebo





Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk not described
Allocation concealment? Low risk centralized randomisation procedure
Blinding?
All outcomes
Low risk patients, physicians and sponsor were all blinded
to treatment assignment and post-randomisation
immune response and CA-125 measurements
Braly 2009
Methods Randomized Controlled phase II Trial
Participants 40 stage III/IV ovarian cancer patients after primary debulking surgery with or without residual
disease
Interventions Intravenous monoclonal antibody (oregovomab - CA125): concurrent (SIM) or delayed (OWD)
with standard carboplatin/paclitaxel primary chemotherapy
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Braly 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk block randomisation
Allocation concealment? Unclear risk not described
Blinding?
All outcomes
High risk patient and physician not blinded to treatment allocation;
blinding of outcome assessor not described
Brossart 2000
Methods Uncontrolled phase I/II study
Participants 10 patients withmeasurable residual or recurrent breast or ovarian cancer (3 ovarian cancer patients)






Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Chianese-Bullock 2008
Methods Uncontrolled phase I study
Participants 9 ovarian cancer patients with or without residual or recurrent disease after primary therapy
Interventions Subcutaneous & intradermal multi peptide vaccine (FBP, Her-2/Neu & MAGE-A1)
Adjuvant: Montanide ISA-51, GM-CSF
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Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Chu 2008
Methods Randomized Controlled phase I/II study
Participants 14 ovarian cancer patients with complete clinical response to primary therapy (10 received treatment
so far)
Interventions Intradermal peptide pulsed Dendritic Cells (Her-2/Neu, hTERT, PADRE): vaccine alone versus






Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk method of randomisation not described, only abstract
available




High risk patient and physician not blinded to treatment alloca-
tion; blinding of outcome assessor not described
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Diefenbach 2008
Methods Uncontrolled phase I study
Participants 9 ovarian cancer patients with complete clinical response to primary therapy
Interventions Subcutaneous short peptide (NY-ESO-1)
Adjuvant: Montanide ISA-51
Outcomes Survival (time to progression)
Tumor Responses




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Ehlen 2005
Methods Uncontrolled phase II study
Participants 13 ovarian cancer patients with measurable recurrent disease
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (time to progression / survival)
Tumor Responses




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
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High risk uncontrolled trial
Freedman 1998
Methods Randomized Controlled phase II study
Participants 30 ovarian cancer patients previously treated with platinum-based chemotherapy (disease status at
study entry not described)
Interventions Subcutaneous KLH conjugate (Sialyl-Tn) at two different dosages
Adjuvant: detox B





Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk method of randomisation not described, only abstract
available




Low risk double blind study
Gordon 2004
Methods Uncontrolled phase II study
Participants 20 ovarian cancer patients with recurrent disease
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (time to progression / survival)
Tumor Responses
Immune Responses: humoral (Ab2, Ab3, HAMA), cellular
Adverse Events
Notes
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Gordon 2004 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Gulley 2008
Methods Uncontrolled phase I/II study
Participants 25patientswithCEAorMUC1over-expressingmetastatic cancerwith progressive disease following
standard chemotherapy (ovarian cancer n = 3)
Interventions Subcutaneous recombinant pox virus (CEA, MUC1): 1x vaccinia, ≥4 fowlpox
Adjuvant: local GM-CSF
Outcomes Survival (progression free survival / overall survival)




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Herrin 2007
Methods Randomized Controlled phase II study
Participants 21 stage III/IV or recurrent ovarian cancer patients with no evidence of disease
Interventions Subcutaneous short peptide versus intravenous peptide pulsed Dendritic Cells (p53)
Adjuvant: Montanide ISA-51 + GM-CSF + IL-2 (peptide) vs IL-2 (dendritic cells)
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Herrin 2007 (Continued)






Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk method of randomisation not described, only abstract
available




High risk patient and physician not blinded to treatment alloca-
tion; blinding of outcome assessor not described
Leffers 2009a
Methods Uncontrolled phase II study
Participants 20 epithelial ovarian cancer patients with (biochemical) recurrence not (yet) eligible for renewed chemotherapy
Interventions Subcutaneous synthetic long peptides (p53)
Adjuvant: Montanide ISA51
Outcomes Tumor Responses





Participants 4 ovarian cancer patients (disease status at study entry not described)
Interventions monoclonal antibody (MJ01- CA125)
Outcomes Immune Response: cellular
Notes
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Ma 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
MacLean 1992
Methods Uncontrolled phase I study
Participants 10 ovarian cancer patients with residual or recurrent disease







Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
MacLean 1996
Methods Uncontrolled phase II study
Participants 34 ovarian cancer patients with evaluable residual or recurrent disease
Interventions Subcutaneous KLH conjugate (Sialyl-Tn)
Adjuvant: detox B
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MacLean 1996 (Continued)




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Method 2002
Methods Randomized Controlled Study
Participants 102 ovarian cancer patients after primary therapy (disease status at study entry not described)
Interventions Intravenous monoclonal antibody (oregovomab - CA125): 2 gifts versus 3 gifts, versus 6 gifts
Outcomes Tumor Responses




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk method of randomisation not described, only abstract available
Allocation concealment? Unclear risk method of randomisation not described, only abstract available
Blinding?
All outcomes
High risk patient and physician not blinded to treatment allocation; blind-
ing of outcome assessor not described
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Mohebtash 2009
Methods Uncontrolled study
Participants 31 metastatic ovarian and breast cancer patients (ovarian cancer n = 17)
Interventions Subcutaneous recombinant pox virus (MUC1 and CEA)
adjuvant: local GM-CSF
Outcomes Survival: median time to progression 2 months (range 1-36)
Adverse Events: no severe adverse events, mostly locoregional grade 1 or 2 reactions
Notes max. 3 patients overlap with Gulley 2008
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Möbus 2003
Methods Retrospective uncontrolled study
Participants 44 ovarian cancer patients with clinical recurrence after primary therapy
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (time first dose to death / overall survival)




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
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Nicholson 2004
Methods Uncontrolled phase I study
Participants 26 epithelial ovarian cancer patients with residual disease (n = 19), microscopic disease (n = 3) after
chemotherapy or 2nd complete remission (n = 4)
Interventions monoclonal antibody (HMFG1 - Muc1); first gift intraperitoneal (n = 16) or intravenous (n = 10)
, then id boosts
Adjuvant: aluminium hydroxide
Outcomes Tumor Responses




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Nishikawa 2006
Methods Uncontrolled phase II study
Participants 4 epithelial ovarian cancer patients after primary debulking surgery (disease status at study entry
not described)
Interventions short peptide (NY-ESO-1)
Adjuvant: incomplete Freund’s adjuvant
Outcomes Immune Responses: cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
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High risk uncontrolled trial
Noujaim 2001
Methods Retrospective uncontrolled study
Participants 184 ovarian cancer patients with clinically or radiologically suspected recurrence
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (overall survival)
Immune Responses: humoral (Ab3), cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Odunsi 2007
Methods Uncontrolled phase I study
Participants 18 ovarian cancer patients after chemotherapy for primary or recurrent disease with or without
residual disease
Interventions Subcutaneous short peptide (NY-ESO-1)
Adjuvant: incomplete Freund’s adjuvant
Outcomes Survival: median time to progression 19.0 months
Tumor Responses: 1x CR, 17x unknownnown
Immune Responses: humoral, cellular
Adverse Events: well-tolerated, no further description
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Odunsi 2007 (Continued)
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Odunsi 2007a
Methods Uncontrolled phase I/II study
Participants 19 ovarian cancer patients without evidence of disease after primary therapy
Interventions intradermal recombinant virus (NY-ESO-1); 1x vaccinia virus, 6x fowlpox boost
Outcomes Survival (disease free survival)




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Pfisterer 2006
Methods Uncontrolled phase I study
Participants 36 Stage I-IV ovarian cancer patients within 6weeks after completion of chemotherapy for recurrent
disease (disease status at study entry not described)
Interventions Subcutaneous monoclonal antibody (abagovomab - CA125)
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Pfisterer 2006 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Reinartz 2004
Methods Uncontrolled multicenter phase Ib/II study
Participants 119 patients with ovarian cancer after at least primary treatment (disease status at entry not de-
scribed)
Interventions Intramuscular monoclonal antibody (ACA125 - CA125)





Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Sabbatini 2000
Methods Uncontrolled phase I study
Participants 25 ovarian cancer patients with complete clinical response to chemotherapy after residual or recur-
rent disease following primary therapy
Interventions Subcutaneous KLH conjugate (LewisY penta saccharide - MUC-1)
Adjuvant: QS-21
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Sabbatini 2000 (Continued)





Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Sabbatini 2006
Methods Randomized, open-label multicenter phase I study
Participants 42 stage II-IV ovarian cancer patients after chemotherapy for recurrence of disease with complete
clinical response or measurable disease (<2 cm)
Interventions Intramuscular (i.m.) or subcutaneous (s.c.) monoclonal antibody (abagovomab - CA125): 4 cohorts
(2x i.m.; 2x s.c.; 0.2mg or 2mg)
Outcomes Survival (time to progression)
Tumor Responses




Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk standard 2x2 factorial design
Allocation concealment? Unclear risk not described
Blinding?
All outcomes
Unclear risk patient and physician not blinded to treatment
allocation; blinding of outcome assessor not de-
scribed
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Sabbatini 2007
Methods Uncontrolled phase I/II study
Participants 11 epithelial ovarian cancer patients with complete clinical remission after primary therapy or
chemotherapy for recurrent disease
Interventions subcutanous heptavalent KLH conjugate (GM2, Globo-H, Lewis Y, Tn-MUC1, Tn(c) sTN(c),
TF(c))




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Sandmaier 1999
Methods Uncontrolled phase II study
Participants 40 breast or ovarian cancer (n = 7) patients who underwent high-dose chemotherapy and autologous
or syngeic stem cell rescue (disease status at study entry unknown)
Interventions subcutanous KLH conjugate (Sialyl-Tn)
Adjuvant: detox B
Outcomes Immune Responses: humoral, cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
34Antigen-specific active immunotherapy for ovarian cancer (Review)




High risk uncontrolled trial
Schultes 1998
Methods Retrospective Uncontrolled study
Participants 75 stage I-IV ovarian cancer patients (disease status at study entry not described)
Interventions Intravenous monoclonal antibody (oregovomab - CA125)
Outcomes Survival (overall survival)
Immune Responses: humoral (Ab2, Ab3, HAMA)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Ströhlein 2009
Methods Uncontrolled phase I study
Participants 9 patients with progressive peritoneal carcinomatosis (ovarian cancer n = 2)
Interventions Intraperitoneal trifunctional antibody targeting EpCAM (n = 1) or Her2/Neu (n = 1)
Outcomes Survival: not reported separately for ovarian cancer patients
Tumor Responses




Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
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Ströhlein 2009 (Continued)
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Tsuda 2004
Methods Uncontrolled phase I/II study
Participants 14 patients with gynaecological cancer after primary therapy (ovarian cancer n = 5; NED n = 2)
Interventions Subcutaneous individualised short peptide cocktail
Adjuvant: Montanide ISA-51
Outcomes Tumor Responses
Immune Responses: humoral, cellular
Adverse Events: not separately described for ovarian cancer patients
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
van Zanten-Przybysz 2002
Methods Uncontrolled phase I/II study
Participants 5 patients with residual or recurrent ovarian cancer after primary debulking surgery and at least
one course of chemotherapy
Interventions Intravenous monoclonal antibody (c-MOv18 - membrane folate receptor)
Outcomes Survival: median time first dose to death 22.0 months
Tumor Responses: 3x PD, 2x SD
Immune Responses: cellular
Adverse Events: max. grade I events
Notes
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van Zanten-Przybysz 2002 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Wagner 1993
Methods Retrospective Uncontrolled study
Participants 58 patients with advanced stage ovarian cancer after primary treatment with high pre-operative
CA-125 levels (disease status at study entry not described)
Interventions Intravenous monoclonal antibody fragments (F(Ab)2-fragements of MAb OC125 - CA125)
Outcomes Survival
Tumor Responses
Immune Responses: humoral (Ab2), cellular
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk uncontrolled trial
Allocation concealment? High risk uncontrolled trial
Blinding?
All outcomes
High risk uncontrolled trial
Characteristics of excluded studies [ordered by study ID]
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Study Reason for exclusion
Anderson 2000 only one EOC patient; no AASI
Bender 2007 only one EOC patient
Carbone 2005 only one EOC patient
Disis 1999 impossible to distinguish between other and ovarian cancer patients
Disis 2000 impossible to distinguish between other and ovarian cancer patients
Disis 2002 impossible to distinguish between other and ovarian cancer patients
Disis 2002a only one EOC patient
Disis 2004 impossible to distinguish between other and ovarian cancer patients
Disis 2004a only one EOC patient
Hernando 2002 autologous tumour lysate vaccine
Hernando 2007 only one EOC patient
Holmberg 2000 impossible to distinguish between breast & ovarian cancer patients
Hui 1997 no AASI
Jager 2006 only one EOC patient
Knutson 2001 only one EOC patient
Knutson 2002 EOC patients withdrew before evaluation of immune responses
Letsch 2008 impossible to distinguish between other and ovarian cancer patients
Loveland 2006 only one EOC patient
Marshall 2005 only one ovarian cancer patient
Miotti 1999 autologous T-cell vaccine
Morse 1999 impossible to distinguish between other and ovarian cancer patients
Morse 2003 uncertain if and how many ovarian cancer patients were included
Murray 2002 only one EOC patient
38Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Parkhurst 2004 no EOC patients
Reddish 1996 impossible to distinguish between other and ovarian cancer patients
Salazar 2006 impossible to distinguish between other and ovarian cancer patients
Schiffman 2002 no immunizations carries out
Yacyshyn 1995 additional results to MacLean 1992; irrelevant for review
Zaks 1998 impossible to distinguish between other and ovarian cancer patients
Characteristics of ongoing studies [ordered by study ID]
NCT00017537
Trial name or title phase IB Trial of Active Specific Immunotherapy With MVF-HER-2(628-647) and CRL1005 Copolymer
Adjuvant in Patients With Metastatic Cancer
Methods Uncontrolled phase Ib study
Participants 5-25 Histologically confirmed metastatic and/or recurrent solid tumour, especially the following: Breast,
Ovarian, Non-small cell lung cancer, and Gastric adenocarcinoma patients
Interventions i.m. MVF-HER-2(628-647)-CRL 1005 vaccine
Outcomes optimum biologic dose
toxicity
clinical responses




Trial name or title Vaccine therapy with tumour specific mutated p53 or ras peptides alone or in combination with cellular
immunotherapy with peptide activated lymphocytes (PAL cells) along with subcutaneous IL-2
Methods Phase II study
Participants max. 70 patients with incurable advanced cancer expressing mutant p53 or ras
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NCT00019084 (Continued)
Interventions patient-specific mutant p53 or ras peptide pulsed antigen-presenting cells plus GM-CSF, or




Starting date February 1996
Contact information
Notes Completion date not mentioned. No published records available
NCT00019916
Trial name or title Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Adenocarcinoma of the Breast
or Ovary
Methods Randomized phase I/II study
Participants max. 34 patients with adenocarcinoma of breast or ovary without therapeutic options
Interventions s.c. p53 peptide vaccine, or




Starting date June 2000
Contact information
Notes Completion date not mentioned. No published records available
NCT00023634
Trial name or title An Early Phase Study of an EGFRvIII Peptide Based Vaccine in Patients With EGFRvIII Expressing Cancers
Methods Phase I study
Participants 24 patients with gastric, ovarian or prostate cancer or anaplastic astrocytoma (ovarian cancer patients in first
complete remission)
Interventions s.c. EGFRvIII peptide admixed with GM-CSF, or
i.d. EGFRvIII peptide admixed with keyhole limpet hemocyanin
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Trial name or title A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Ep-
ithelial Carcinoma
Methods Randomized phase I/II study
Participants 24 stage III/IV ovarian cancer after primary therapy
Interventions OvaRex MAb-B43.13 ascites fluid product and/or OvaRex MAb-B43.13 cell culture product
Outcomes Safety
Survival
Starting date March 2002
Contact information
Notes Study completion December 2007. No published records available
NCT00034372
Trial name or title Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for
Ovarian Carcinoma
Methods Phase II
Participants 102 ovarian cancer patients with complete clinical response to primary treatment




Starting date September 2000
Contact information
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NCT00034372 (Continued)
Notes Study completion December 2007. No published records available
NCT00091000
Trial name or title An Open Label Pilot Study to Evaluate the Safety and Tolerability of PANVAC-V (Vaccinia) and PANVAC-
F (Fowlpox) in Combination With Sargramostim in Adults With Metastatic Carcinoma
Methods Phase II
Participants 51patientswith histologically confirmed colorectal, non-colorectal, ovarian, or breast carcinomawith evidence
of disease










Trial name or title Evaluation of the Immunogenicity of Vaccination With Synthetic Peptides in Adjuvant in Patients With
Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Methods Phase II study
Participants 28 primary stage III/IV ovarian cancer patients
Interventions neoadjuvant paclitaxel/carboplatin followed by surgical debulking, vaccine therapy*, adjuvant paclitaxel/
carboplatin or,
surgical debulking, vaccine therapy*, followed by adjuvant paclitaxel/carboplatin
*i.d. & s.c. synthetic peptides, (MAGE-A1:161-169, FBP:1901-199, Her-2/neu:369-377, MAGE-A1:96-
104, and Her-2/neu:754-762) and tetanus toxoid helper peptide
adjuvant: Montanide ISA-51
Outcomes Immune responses
Starting date April 2006
Contact information
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Trial name or title A Phase 1Open-Label Study of the Safety and Feasibility of ZYC300AdministrationWithCyclophosphamide
Pre-Dosing
Methods Phase I
Participants 22 advanced stage malignancies with evidence of disease and no therapeutic options





Starting date November 2006
Contact information
Notes Study completion January 2009. No published records available
NCT00418574
Trial name or title A Randomised,Double Blind, Placebo Controlled, Multicentre Trial of Abagovomab Maintenance Therapy
in Patients With Epithelial Ovarian Cancer After Complete Response to First Line Chemotherapy
Methods Randomised Placebo Controlled trial
Participants 870 ovarian cancer patients with complete clinical response to primary therapy




Starting date December 2006
Contact information
Notes
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NCT00437502
Trial name or title A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA-51) as Consolida-
tion Following Optimal Debulking and Systemic Chemotherapy for WomenWith Advanced Stage Ovarian,
Tubal, or Peritoneal Cancer
Methods Phase I study
Participants 18 stage III/IV ovarian cancer patients with complete clinical response to primary therapy








Trial name or title A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune
Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who
Are Not Candidates for Standard Treatment
Methods Phase I study
Participants 17
Interventions i.v. Live-attenuated Listeria monocytogenes expressing human Mesothelin
i.v.
Outcomes Dose-limiting toxicities
Starting date December 2007
Contact information
Notes Study completion February 2009. No published records available
NCT00616941
Trial name or title A Phase I Study of NY-ESO-1Overlapping Peptides (OLP4)With orWithout Immunoadjuvants Montanide
and Poly-ICLC Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal
Cancer Patients in Second or Third Remission
Methods Phase I
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NCT00616941 (Continued)
Participants 26 stage II-IV ovarian cancer patients in second or third complete clinical remission
Interventions s.c. NY-ESO-1 OLP4 alone, with Montanide or with Montanide and Poly-ICLC
Outcomes Safety
Immune Responses




Trial name or title A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted
hCG-β Vaccine, in Patients With Incurable Locally Advanced or Metastatic Breast, Colorectal, Pancreatic,
Bladder and Ovarian Cancer
Methods Phase I study
Participants 26 patients with incurable, metastatic or locally advanced breast, colorectal, pancreatic, bladder or ovarian
cancer
Interventions i.v. CDX-1307 (a fusion protein composed of a mannose receptor -specific immunoglobulin human mono-
clonal antibody and the hCG-β antigen)
Outcomes Safety
Clinical Responses




Trial name or title A Randomized Phase III Trial in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer With
a Polyvalent Vaccine-KLH Conjugate + OPT-821 versus OPT-821
Methods Randomised phase III trial
Participants 164 ovarian cancer patients in second or third complete clinical remission
Interventions s.c. polyvalent antigen-KLH conjugate vaccine in combination with s.c. OPT-821, or
s.c. OPT-821
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Starting date August 2008
Contact information
Notes possibly same study as NCT00857545
NCT00709462
Trial name or title A Phase I, Open-Label, Dose-Escalation, Multidose Study of CDX-1307, a Mannose Receptor-Targeted
hCG-β Vaccine, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX-
1307-01)
Methods Phase I study
Participants 48 patients with breast, colorectal, pancreatic, ovarian or bladder cancer without therapeutic options
Interventions i.d. CDX-1307 (a fusion protein composed of a mannose receptor -specific immunoglobulin human mono-
clonal antibody and the hCG-β antigen)








Trial name or title Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM in Patients With Epithelial Ovarian, Fallopian Tube
or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Methods Phase I
Participants 12 stage II-IV ovarian cancer patients with complete response to primary or secondary (chemo)therapy
Interventions s.c. ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine plus s.c. GM-CSF
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Trial name or title p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer a Phase II Trial
Methods Uncontrolled phase II study
Participants 19 ovarian cancer patients with (bio-chemically) recurrent disease after prior therapy









Trial name or title A Phase III Randomized, Double-Blind Trial of a Polyvalent Vaccine-KLHConjugate (NSC 748933) +OPT-
821 versus OPT-821 in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Who Are in
Second or Third Complete Remission
Methods Randomized phase III study
Participants 164 stage II-IV ovarian cancer patient in second or third clinical remission
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NCT00857545 (Continued)
Starting date January 2009
Contact information
Notes possibly same study as NCT00693342
NCT00887016
Trial name or title Open Label Phase I Study to Evaluate the Safety and Tolerability of Vaccine (GI-6207) Consisting of Whole,
Heat-Killed Recombinant Saccharomyces Cerevisiae Genetically Modified to Express CEA Protein in Adults
With Metastatic CEA-Expressing Carcinoma
Methods Phase I study
Participants 28 CEA-overexpressing cancer patients without therapeutic options









Trial name or title A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2’-Deoxycytidine
(Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary
Peritoneal Carcinoma
Methods Phase I
Participants 18 ovarian cancer patients with recurrent disease
Interventions decitabine in combination with NY-ESO-1 peptide vaccine (emulsified with incomplete Freund’s adjuvant




Starting date April 2009
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S






Sample Definition and Selection
Are the inclusion and exclusion criteria clearly defined?
Is the study population a representative selection of the true
population?








Are the interventions clearly defined (type of vaccine, anti-
gen, adjuvant, route of vaccination and vaccination sched-
ule)?









Are the selected outcome measures clearly specified?
Are the outcome measures relevant?









Is there an adequate rationale for the number of patients
included?
Is there an adequate description of withdrawal / exclusion
of patients during the study?




Table 2. Overview of included studies
Study Design N Disease status Target antigen Type of intervention
Berek 2001 RCT 252 NED
after primary surgery and
chemotherapy
CA-125 antibody versus placebo
Berek 2004 RCT 145 NED
after primary surgery and
chemotherapy
CA-125 antibody versus placebo
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Table 2. Overview of included studies (Continued)
Berek 2009 RCT 317 NED
after primary surgery and
chemotherapy
CA-125 antibody versus placebo
Braly 2009 RCT 40 NED or ED after pri-
mary surgery
CA-125 antibody (concurrent or
delayed with standard
chemotherapy)
Brossart 2000 uncontrolled phase
I/II
3 residual or recurrent dis-
ease











Chu 2008 RCT 14 NED





cells (alone or after sin-
gle dose of cyclophospha-
mide)
Diefenbach 2008 uncontrolled phase
I
9 NED
after primary surgery and
chemotherapy
NY-ESO-1 short peptide
Ehlen 2005 uncontrolled phase
II
13 measurable recurrent dis-
ease
CA-125 antibody
Freedman 1998 RCT 30 unknown Sialyl-Tn KLH conjugate
Gordon 2004 uncontrolled phase
II
20 recurrent disease CA-125 antibody
Gulley 2008 uncontrolled phase
I/II
3 progressive disease after
standard chemotherapy
CEA, MUC1 recombinant virus
Herrin 2007 RCT 21 NED after prior therapy
for primary or recurrent
disease
p53 short peptide versus pep-
tide-pulsed dendritic cells
Leffers 2009a uncontrolled phase
II
20 recurrent disease p53 long peptides
Ma 2002 uncontrolled 4 unknown CA-125 antibody
MacLean 1992 uncontrolled phase
I
10 residual or recurrent dis-
ease
Thomson Friedenreich KLH conjugate
MacLean 1996 uncontrolled phase
II
34 residual or recurrent dis-
ease
Sialyl-Tn KLH conjugate
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Table 2. Overview of included studies (Continued)
Method 2002 RCT 102 unknown CA-125 antibody (2 vs 3 vs 6 gifts)
Möbus 2003 retrospective
uncontrolled
44 recurrent disease after pri-
mary therapy
CA-125 antibody
Mohebtash 2009 uncontrolled 17 metastatic disease CEA, MUC1 recombinant virus
Nicholson 2004 uncontrolled phase
I
26 residual disease after pri-
mary therapy or 2nd
complete remission
MUC1 antibody
Nishikawa 2006 uncontrolled phase
II
4 unknown NY-ESO-1 short peptide
Noujaim 2001 retrospective
uncontrolled
184 recurrent disease CA-125 antibody
Odunsi 2007 uncontrolled phase
I
18 NED or ED after chemo-
therapy for primary or re-
current disease
NY-ESO-1 short peptide
Odunsi 2007a uncontrolled phase
I/II
19 NED after primary ther-
apy
NY-ESO-1 recombinant virus
Pfisterer 2006 uncontrolled phase
I
36 unknown CA-125 antibody
Reinartz 2004 uncontrolled phase
Ib/II
119 unknown CA-125 antibody
Sabbatini 2000 uncontrolled phase
I
25 NED after chemotherapy
for primary or recurrent
disease
MUC1 KLH conjugate
Sabbatini 2006 RCT 42 NED or ED (<2cm) af-




Sabbatini 2007 uncontrolled phase
I/II
11 NED after chemotherapy







Sandmaier 1999 uncontrolled phase
II
7 unknown Sialyl-Tn KLH conjugate
Schultes 1998 retrospective
uncontrolled
75 unknown CA-125 antibody
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Table 2. Overview of included studies (Continued)
Ströhlein 2009 uncontrolled phase
I
2 progressive disease EpCAM or Her-2/Neu trifunctional antibody
Tsuda 2004 uncontrolled phase
I/II





5 residual or recurrent dis-
ease after prior chemo-
therapy
membrane folate receptor antibody
Wagner 1993 retrospective
uncontrolled
58 unknown CA-125 antibody
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Möbus
2003



























184 yes yes yes no un-
known
yes yes yes no no yes
Odunsi
2007
18 no no yes yes un-
known


























25 yes yes yes yes un-
known














no yes no no yes yes no yes yes
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no yes yes no no yes
Ströhlein
2009
2 yes no no yes un-
known
yes yes yes no yes yes
Tsuda
2004







5 yes no yes yes un-
known







no yes no no no no
unknown - unknownnown
Table 5. Evaluation of clinical responses to immunotherapy














Berek 2009 371 no
Braly
2009
18/22 yes unknown yes unknown cCR 15x / 18x
Brossart
2000




9 yes both unknown unknown 1x NED, 8x
PD
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Table 5. Evaluation of clinical responses to immunotherapy (Continued)
Chu
2008




9 yes both unknown unknown not reported
Ehlen
2005





4x , 1x =, 6x unknown 3x SD, 10x PD
Freedman
1998




20 yes both unknown 6x unknown 2x NED, 2x
CR, 1x PR, 1x
SD, 9x PD
Gulley 2008 3 yes both unknown unknown not reported

























26 yes CA-125 unknown 21x PD, 1x
SD, 1x l.f.u.,
3x unknown
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5 yes both unknown 1x , 1x =, 1x ,
2x unknown
unknown 1x NED, 1x





58 yes CA-125 unknown not reported
l.f.u. - lost in follow-up; cCR - complete clinical remission; CR - complete response; PR - partial response; SD - stable disease; PD -
progressive disease; NED - no evidence of disease
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Table 6. Definitions and results of survival analysis in antigen-specific antibody studies
Study analysed definition results
Berek 2001 yes time to relapse NS: median TTR placebo 11.3, robust
HAMA 16.4, and robust Ab2 18.9 months
Berek 2004 yes time to relapse / overall survival NS: TTR oregovomab 24.0 vs. placebo 10.
8 months (HR 0.543, 95%CI 0.287-1.025)
; OS 57.5 oregovomab vs. 48.6 placebo (HR
0.72, 95%C.I. 0.41-1.25)
Berek 2009 yes time to relapse (randomisation to relapse) NS: median TTR oregovomab 10.3 months
vs placebo 12.9 months
Braly 2009 yes progression free survival NS: median PFS simultaneous administra-
tion 17.9 months vs. delayed administration
16.1 months
Ehlen 2005 yes time to progression / survival (first dose to
death)
TTP median 8.4 weeks (range 2-61 weeks);
survival 37 weeks (range 11-110)
Gordon 2004 yes time to progression / survival (first dose to
death)
TTP median 11 weeks (T-cells responders
vs non-responders p<0.0001 HR 0.150,
95%CI 0.006-0.168); survival median 70.4
weeks (T-cell responders vs non-responders
P<0.002 HR 0.157, 95%CI 0.009-0.347)
Ma 2002 no
Method 2002 no
Möbus 2003 yes survival (first dose to death) / overall survival
(diagnosis to death)
survival median 16.8 months 95% CI 10.
3-22.6 (Ab3 responders vs non-responders
18.2 vs 13.1, p=0.0896; HAMA respon-
ders vs non-responders 22.6 months vs 7.6
months, p=0.0016); overall survival median
34.4 months
Nicholson 2004 no
Noujaim 2001 yes survival (first dose to death) median survival & 3-year survival: Ab3 re-
sponders vs non-responders 22.9 vs 13.5
months, p=0.0089 ? 38% vs 8%; T-cell re-
sponders vs non-responders (n = 16) >84 vs
13.2 months, p=0.0202 ? 75% vs 0%
Pfisterer 2006 no
59Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 6. Definitions and results of survival analysis in antigen-specific antibody studies (Continued)
Reinartz 2004 yes survival (first dose to death) median survival 19.4 months, Ab3 respon-
ders vs non-responders: 23.4 vs 4.9 months,
p<0.0001
Sabbatini 2006 yes time to progression TTP: 4 months (95%CI 3-5 months)
Schultes 1998 yes overall survival (diagnosis to death) median OS: robust Ab3 responders vs non-
robust responders 49 vs 38 months , p=0.
0029; Ab2 robust vs non-robust responders
30.0 vs 44.0 months, p=0.0475
Ströhlein 2009 yes overall survival not described separately for ovarian cancer
patients
van Zanten-Przybysz 2002 yes survival (first dose to death) median survival 22.0 months
Wagner 1993 yes not described survival robust Ab2 vs non-robust Ab2 re-
sponders NS
Table 7. Definitions and results of survival analysis in other antigen-specific immunotherapy studies




Diefenbach 2008 yes time to progression (last chemo to relapse) median TTP 13.0 months (95%CI 11.2 - not
reached)
Freedman 1998 yes progression free interval; survival median PFI 4 months (95%CI 1.9-7.6); me-
dian survival 13.3. months (95%CI 1.5-30.8)
Gulley 2008 yes progression free survival; overall survival PFS: 9, 18, 19+ months; OS: 6, 19+, 21
months
Herrin 2007 yes progression free survival; overall survival mean PFS 5 months; mean OS SQ vs. IV 70.
4 vs. 72.9 months
Leffers 2009a no
MacLean 1996 yes survival (trial entry to death) median survival 12.7 months
MacLean 1992 no
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Table 7. Definitions and results of survival analysis in other antigen-specific immunotherapy studies (Continued)
Mohebtash 2009 yes time to progression median TTP 2 months (range 1-36)
Nishikawa 2006 no
Odunsi 2007 yes time to progression (first vaccination to re-
lapse)
median TTP 19.0 months (95% CI 9.0 - not
reached)
Odunsi 2007a yes disease free survival median DFS 19.9 months
Sabbatini 2000 yes time to progression (trial entry to relapse) median TTP 6 months (range 2-17)
Sabbatini 2007 yes time to progression (first vaccination to re-
lapse)
median TTP 4.2 months (95% CI 2.7-8.5)
Sandmaier 1999 no
Tsuda 2004 no
TTR - time to relapse; PFI - progression free interval; PFS - progression free survival; DFS - disease free survival; CI - confidence
interval; SQ - subcutaneous; IV - intravenous
Table 8. Definitions and results of anti-idiotypic (Ab2) humoral responses in antigen-specific monoclonal antibody studies
Study N Dose target
antigen
analysed positive if: % positive robust if: % robust
Berek 2001 252 2mg CA-125 no >50ng/ml 63% >100ng/ml
Berek 2004 145 2mg CA-125 no >100ng/ml 67%
Berek 2009 371 2mg CA-125 no unknown n.r. unknown n.r.
Braly 2009 40 unknown CA-125 yes >100ng/ml 94% vs 74%
Ehlen 2005 13 2mg CA-125 yes >50ng/ml 45%
Gordon
2004
20 2mg CA-125 yes >50ng/ml >100ng/ml 79%
Ma 2002 4 unknown CA-125 no
Method
2002
102 2mg CA-125 no >100ng/ml 13% vs 31% vs 67%
Möbus
2003
44 2mg CA-125 yes >50ng/ml 77%
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26 25mg MUC1 yes unknown 100%
Noujaim
2001
184 2mg CA-125 yes
Pfisterer
2006
36 2mg CA-125 yes
Reinartz
2004
119 2mg CA-125 yes
Sabbatini
2006
42 2mg/0.2mg CA-125 yes
Schultes
1998

















58 1mg CA-125 no >0u/l 64% >10u/l 32%
n.r. - not reported; *increased titers in patients treated with 90-Y-muHMFG1 (n = 208) compared to standard treatment (n = 199)
Table 9. Definitions and results of anti-anti-idiotypic (Ab3) humoral responses in antigen-specific antibody studies
Study N Dose target
antigen
analysed positive if: % positive robust if: % robust
Berek 2001 252 2mg CA-125 no
Berek 2004 145 2mg CA-125 no
Berek 2009 371 2mg CA-125 no
Braly 2009 40 unknown CA-125 no
Ehlen 2005 13 2mg CA-125 yes >100ng/ml >3x baseline 0%
Gordon
2004
20 2mg CA-125 yes >100ng/ml >3x baseline 10,5%
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Table 9. Definitions and results of anti-anti-idiotypic (Ab3) humoral responses in antigen-specific antibody studies (Con-
tinued)
Ma 2002 4 unknown CA-125 no
Method
2002
102 2mg CA-125 no
Möbus
2003
44 2mg CA-125 yes >3x baseline 28%
Nicholson
2004
26 25mg MUC1 yes >0.015ug/ml 38%
Noujaim
2001
184 2mg CA-125 yes >3x baseline 43%
Pfisterer
2006




119 2mg CA-125 yes >1000u/ml 68%
Sabbatini
2006
42 2mg/0.2mg CA-125 yes >1000u/ml 100%
Schultes
1998

















58 1mg CA-125 no
Table 10. Definitions and results of humoral response evaluation in other antigen-specific immunotherapy studies
Study N target antigen(s) analyzed assay positive if: % positive








Chu 2008 14 Her-2/Neu,
hTERT, PADRE
no
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Table 10. Definitions and results of humoral response evaluation in other antigen-specific immunotherapy studies (Continued)
Diefenbach
2008
9 NY-ESO-1 yes ELISA >100 0%
Gulley 2008 3 CEA, MUC1 no
Freedman 1998 30 Sialyl Tn no
Herrin 2007 21 p53 no
Leffers 2009a 20 p53 yes unknown unknown pre-imm: 40%, post-imm:
45%
MacLean 1992 10 Thomson Frieden-
reich
yes ELISA unknown 80% IgA, 90% IgM, 90%
IgG, 0% IgE
MacLean 1996 34 Sialyl Tn yes ELISA unknown 96%
Mohebtash 2009 17 MUC1, CEA no
Nishikawa 2006 4 NY-ESO-1 no
Odunsi 2007 18 NY-ESO-1 yes ELISA unknown 22%
Odunsi 2007a 19 NY-ESO-1 yes ELISA unknown 38%
Sabbatini 2000 25 Lewis Y yes ELISA unknown 67%
Sabbatini 2007 11 GM2, Globo-
H, Lewis Y, Tn-
MUC1, Tn(c) sTN
(c), TF(c)
yes ELISA negative to ≥ 1:40 or 8-fold
increase
89% ≥3 antigens; 22%
GM2, 33% Globo-H, 11%
Lewis Y, 100% Tn-MUC1,
44% Tn(c), 44% sTN(c),
78% TF(c)
Sandmaier 1999 7 Sialyl Tn yes ELISA ≥1:20 100% IgM, 80% IgG
Tsuda 2004 5 patient-tailored
cocktail
yes ELISA unknown 67%
Table 11. Definitions and results of cellular responses in antigen-specific antibody studies
Study N Dose target antigen analysed assay positive if: % positive
Berek 2001 252 2mg CA-125 no
Berek 2004 145 2mg CA-125 no
Berek 2009 371 2mg CA-125 no
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Table 11. Definitions and results of cellular responses in antigen-specific antibody studies (Continued)
Braly 2009 40 unk CA-125 yes ELISPOT permutation test 44% vs. 21%
Ehlen 2005 13 2mg CA-125 yes ELISPOT permutation test n = 4 CA-125:
75%; n = 3 ore-
govomab 67%
Gordon 2004 20 2mg CA-125 yes ELISPOT permutation test n = 18 CA-125:
39%; n = 18 ore-
govomab 50%; n
= 8 autologous tu-
mour cells 63%
Ma 2002 4 unk CA-125 yes proliferation assay unknown n = 4: 50%
Method 2002 102 2mg CA-125 yes ELISPOT NR NR
Möbus 2003 44 2mg CA-125 no
Nicholson
2004
26 25mg MUC1 no
Noujaim
2001







n = 17 CA-
125 53%; Th1 cy-
tokines 41%, Th2
cytokines 94%





L vs S: n = 12 vs
17, CD4: 58% vs
29%; CD8 75%
vs 18%
Reinartz 2004 119 2mg CA-125 no
Sabbatini
2006
42 2mg/0.2mg CA-125 yes ELISPOT spots experimen-




n = 5: 80%









unknown EpCAM n = 1
(100%)
Her2/Neu n = 1
(0%)
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yes proliferation assay unknown 0%




NR - not reported
Table 12. Definitions and results of cellular responses in other antigen-specific immunotherapy studies
Study N target antigen(s) analysed assay positive if: % positive




unknown n = 1: Her-2/Neu






yes ELISPOT (CD8) unknown n = 9: FBP 40%, Her-
2/neu 83%, MAGE-
A1 83%
Chu 2008 14 Her-2/Neu,
hTERT, PADRE




9 NY-ESO-1 yes ELISPOT / Tetramer
staining (CD8)





both assays n = 9: 67%
Freedman 1998 30 Sialyl Tn no
Gulley 2008 3 CEA, MUC1 yes ELISPOT (CD8) /
IFN-γ ELISA (CD4)
ELISPOT: ≥2-fold in-




n = 3: 100% CEA
n = 3: 33% CEA
Herrin 2007 21 p53 yes ELISPOT unknown n = 13 vs. 7: 69% vs.
71%
Leffers 2009a 20 p53 yes ELISPOT / prolifera-









n = 18: 100%
n = 17: 82%
n = 5: CD8 0%, CD4
100%
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Table 12. Definitions and results of cellular responses in other antigen-specific immunotherapy studies (Continued)
and ≥2x higher than
before imm
intracellular staining:
≥3 higher than before
imm.
MacLean 1992 10 Sialyl Tn no
MacLean 1996 34 Thomson Frieden-
reich
no
Mohebtash 2009 17 MUC1, CEA no
Nishikawa 2006 4 NY-ESO-1 yes ELISPOT (CD4) unknown n = 4: 75%
Odunsi 2007 18 NY-ESO-1 yes ELISPOT (CD4 /
CD8)
ELISPOT: mean ± 3
SD
n = 18: CD4 - 83%; n
= 9: CD8 - 33%
Odunsi 2007a 19 NY-ESO-1 yes ELISPOT (CD4 /
CD8)
unknown n = 9: CD8 - 55%,
CD4 ?
Sabbatini 2000 25 Lewis Y no
Sabbatini 2007 11 GM2, Globo-




Sandmaier 1999 7 Sialyl Tn yes proliferation assay* >upper limit of nor-
mals (SI 2.35)
n = 4 50%
Tsuda 2004 5 patient-tailored
cocktail
yes IFN-γ ELISA unclear n = 2 after 6 vacc.
100%; n = 1 after 12
vacc. 100%
* as measured after at least three immunizations; SI - stimulation index; SD - standard deviation
Table 13. Definitions and results of human-anti-mouse antibody (HAMA) evaluation in antigen-specific antibody studies
Study N Dose target
antigen
analysed positive if: % positive robust if: % robust
Berek 2001 252 2mg CA-125 yes >5000ng/ml 51%
Berek 2004 145 2mg CA-125 yes >200ng/ml unknown >5000ng/ml 59%
Berek 2009 371 2mg CA-125 yes unknown n.r.
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Table 13. Definitions and results of human-anti-mouse antibody (HAMA) evaluation in antigen-specific antibody studies
(Continued)
Braly 2009 40 unk CA-125 yes unknown SIM vs OWD:
100% vs 80%
>3000ng/ml SIM vs OWD:
88% vs 74%
Ehlen 2005 13 2mg CA-125 yes >200ng/ml 100% >5000ng/ml 58%
Gordon
2004
20 2mg CA-125 yes >200ng/ml unknown >5000ng/ml 79%
Ma 2002 4 unk CA-125 no
Method
2002




44 2mg CA-125 yes >5000ng/ml 68%
Nicholson
2004
26 25mg MUC1 no
Noujaim
2001
184 2mg CA-125 no
Pfisterer
2006




119 2mg CA-125 yes >100ng/ml 78%
Sabbatini
2006
42 2mg/0.2mg CA-125 yes >100ng/ml 90%
Schultes
1998

















58 1mg CA-125 no
n.a. - not applicable; n.r. - not reported
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A P P E N D I C E S
Appendix 1. PubMed search strategy
PubMed search
PubMed RCT search filter:
1. randomised controlled trial [pt]
2. controlled clinical trial [pt]
3. randomised [tiab]
4. placebo [tiab]




9. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
10. humans [mh]
11. #9 and #10
PubMed search for patient population:
12. ovary
13. ovarian
14. # 12 OR # 13
15. cancer OR carcinoma OR neoplasm OR tumor OR tumors OR tumour OR tumours OR malignan*
16. # 14 AND # 15
17. ovarian neoplasms [mh]
18. # 16 OR # 17







25. #19 OR #20 OR #21 OR #22 OR #23 OR #24
26. antigen* OR tumor antigen OR tumour antigen
27. Antigens, Neoplasm [mh]
28. # 26 OR # 27
29. T cell OR T-cell OR T lymphocyte OR T-lymphocyte OR CD4-positive T-lymphocyte OR CD8-positive lymphocyte
30. T-lymphocytes [mh]
31. # 29 OR # 30
32. # 25 OR # 28 OR # 31
Search for all types of different trials:
33. # 18 AND # 32 (all trials)
34. #33 AND #10 (all human trials)
35. # 11 AND # 18 AND # 32 (RCT’s only) *
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3. ’randomized controlled trial’/exp
4. ’single-blind procedure’/exp
5. random$ OR crossover$ OR ’cross over’$ OR cross AND over$ OR factorial$ OR placebo$ OR doubl$
adj blind$ OR singl$ adj blind$ OR allocat$ OR assign$ OR volunteer$
6. #1 OR #2 OR #3 OR #4 OR #5
7. ’ovary’ OR ’ovarian’ OR ’ovarium’
8. ’cancer’ OR ’carcinoma’ OR ’neoplasm’ OR ’tumor’ OR ’tumour’ OR ’tumors’ OR ’tumours’ OR ’malignancy’
9. #7 AND #8
10. ’ovary tumor’/exp




15. ’vaccination’ OR ’vaccine’ OR ’immunization’ OR ’immunisation’ OR ’immunotherapy’
16. #12 OR #13 OR #14 OR #15
17. ’tumor antigen’/exp
18. ’t cell’ OR ’t-cell’ OR ’t lymphocyte’ OR ’t-lymphocyte’ OR ’cd4-positive t-lymphocyte’ OR ’cd8-positive t-lymphocyte’
19. ’t lymphocyte’/exp
20. #18 OR #19
21. #16 AND #17 AND #20
22. #11 AND #21 AND [humans]/lim
Appendix 3. CENTRAL search strategy
CENTRAL search
(ovary OR ovarian) AND ((cancer OR carcinoma OR neoplasm OR tumor OR tumors OR tumour OR tumours OR malignan*)
OR (ovarian neoplasms))
and
(immunotherapy OR vaccination OR vaccine OR immunization OR active immunotherapyn OR cancer vaccines)
and
(antigen* OR tumor antigen OR tumour antigen) OR (Antigens Neoplasm)
and
(T cell OR T-cell OR T lymphocyte OR T-lymphocyte OR CD4-positive T-lymphocyte OR CD8-positive lymphocyte)
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Appendix 4. Data extraction form
CRITICAL REVIEW & DATA EXTRACTION FORM











Participants · Total number of participants: ………………
· Number of patients with EOC: …………….
· Age:
o Median + range: ……………………
o Mean + SD: …………………………
· FIGO stage: …………………………………
· Histological tumor type: ……………………
· Tumor grade: ………………………………
· Previous therapy: ……………………………
· Concurrent therapy: ………………………..
Trial intervention · type of vaccine: ………………………………
· antigen used: …………………………………
· adjuvant used: ……………………………….
· route of vaccination: …………………………
· vaccination schedule: ……………………….
Outcomes
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Trial N + reason
Patients excluded during trial
Patients lost to follow up
Clinical responses N









Postimmunotherapy treatment Administered: Yes ? No ?
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Separate information on cytotoxic T-lymphocytes and Thelper lymphocytes available: Yes ? No ?
If yes, specify: ………………………………………………………………………








Type of AE’s · Local events (injection site): Yes ? No ?
If yes, specify: …………………
· Systemic: Yes ? No ?
If yes:
Autoimmunity Yes ? No ?
If yes, specify: ……………………………
Allergic reactions Yes ? No ?
If yes, specify: ……………………………
Other Yes ? No ?
If yes, specify: ……………………………
Other
Contact with primary investigators Clarify Methods ?
Clarify Results ?
Notes
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WH A T ’ S N E W
Last assessed as up-to-date: 30 October 2009.
Date Event Description
27 March 2014 Amended Contact details updated.
C O N T R I B U T I O N S O F A U T H O R S
NL selected relevant studies, assessed study quality, extracted data and wrote the review. HWN selected relevant studies, assessed study
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HMB and BC provided statistical and methodological support. KM supported in writing the review as an expert in immunology.
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TD was added to the team. No further relevant differences between protocol and review.
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75Antigen-specific active immunotherapy for ovarian cancer (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
